Qiagen and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography
Complete the form below to unlock access to ALL audio articles.
Qiagen N.V. and ActiveSight have announced that they have entered into a co-marketing agreement related to protein crystallography for drug discovery.
The agreement seeks to ease access to protein crystallization reagents and crystallographic services, thereby expanding the opportunities for organizations in need of important structural biology information.
Qiagen claims that its extensive line of standardized reagents and kits now enable researchers to use a seamless solution of Qiagen products from genes all the way through to protein crystals.
Crystal analysis and structure resolution can then be performed at ActiveSight, using their advanced equipment for structural determination. ActiveSight also offers protein crystallization set-up using Qiagen reagents.
"We are very pleased to work with ActiveSight, given their reputation for excellence and leadership in the protein crystallography service field," said Jean-Pascal Viola, Qiagen's Director of Protein Crystallization.
"The bundling of Qiagen's sample preparation standards with ActiveSight's advanced service offerings creates an alternative for researchers in need of structural analysis, X-ray analysis and 3D structure resolution of their protein crystals. The endorsement of Dr. McRee validates our leadership position in the field of protein crystallization."
"We are delighted to offer Qiagen's high-quality reagents in our CrystalScan crystallization screening service," stated Duncan McRee, Ph.D., President of ActiveSight.
"Qiagen is leading the field in innovation for crystallization reagents to make structure determination more accessible and successful."
